Arbutus Biopharma Corporation Common Stock (NASDAQ: ABUS) last traded at $4.22, up 0.96% on the session. The quote above updates while this page is open; the figures below are drawn from Arbutus Biopharma Corporation Common Stock’s own filings and are restated only when a new one is published.
Arbutus Biopharma Corporation Common Stock trades on NASDAQ under the ticker ABUS. Its market capitalisation is $834.92 million.
Valuation measures for Arbutus Biopharma Corporation Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $834.92M |
|---|---|
| Enterprise value | $831.04M |
| P/E ratio | 5.34 |
| Price / sales | 4.59 |
| Price / book | 3.23 |
| Beta |
| 1.17 |
Trailing-twelve-month figures tagged in Arbutus Biopharma Corporation Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $181.72M |
|---|---|
| Net income (TTM) | $153.05M |
| EPS (TTM) | $0.790 |
| Operating margin | 81.99% |
| Return on equity | 59.16% |
| Cash | $19.17M |
Range and volume for ABUS over the past 52 weeks.
| 52-week high | $5.45 |
|---|---|
| 52-week low | $3.50 |
| Volume | 3.15M |
| Average volume | 4.69M |
| Previous close | $4.18 |
Invest a chosen dollar amount in Arbutus Biopharma Corporation Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell ABUS.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.